These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10365796)

  • 21. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A study on the clinical and pathological efficacy of lamivudine in the treatment of chronic hepatitis B].
    Yang C; Xiao YH; Guan XQ; Yuan Z
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):364-7. PubMed ID: 15225436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hepatitis B core antigen expression pattern predicts response to lamivudine therapy in patients with chronic hepatitis B].
    Shi KD; Hwang SG; Choi JH; Hwang IJ; Yoon JH; Kim KI; Kwon CI; Hong SP; Park PW; Rim KS
    Korean J Hepatol; 2008 Jun; 14(2):197-205. PubMed ID: 18617767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop.
    Suzuki Y; Arase Y; Ikeda K; Saitoh S; Tsubota A; Suzuki F; Kobayashi M; Akuta N; Someya T; Miyakawa Y; Kumada H
    Intervirology; 2003; 46(3):164-70. PubMed ID: 12867754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children.
    Shapira R; Mor E; Bar-Nathan N; Sokal EM; Tur-Kaspa R; Dinari G; Ben-Ari Z
    Transplantation; 2001 Jul; 72(2):333-6. PubMed ID: 11477362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
    Schiefke I; Klecker C; Maier M; Oesen U; Etzrodt G; Tannapfel A; Liebert UG; Berr F
    Liver Int; 2004 Apr; 24(2):98-104. PubMed ID: 15078472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.
    Chan HL; Leung NW; Hui AY; Wong VW; Liew CT; Chim AM; Chan FK; Hung LC; Lee YT; Tam JS; Lam CW; Sung JJ
    Ann Intern Med; 2005 Feb; 142(4):240-50. PubMed ID: 15710957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy.
    Lai CL; Yuen MF; Hui CK; Garrido-Lestache S; Cheng CT; Lai YP
    J Med Virol; 2002 Jul; 67(3):334-8. PubMed ID: 12116023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.
    Perrillo R; Rakela J; Dienstag J; Levy G; Martin P; Wright T; Caldwell S; Schiff E; Gish R; Villeneuve JP; Farr G; Anschuetz G; Crowther L; Brown N
    Hepatology; 1999 May; 29(5):1581-6. PubMed ID: 10216146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chronic hepatitis B treated with domestic manufactured lamivudine in 2200 patients: a phase IV study].
    Yao GB; Cui ZY; Yao JL; Zhang DF; Ji NX; Huang Y
    Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):103-8. PubMed ID: 12648409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.
    van Nunen AB; Hansen BE; Suh DJ; Löhr HF; Chemello L; Fontaine H; Heathcote J; Song BC; Janssen HL; de Man RA; Schalm SW
    Gut; 2003 Mar; 52(3):420-4. PubMed ID: 12584227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.
    Chang TT; Liaw YF; Wu SS; Schiff E; Han KH; Lai CL; Safadi R; Lee SS; Halota W; Goodman Z; Chi YC; Zhang H; Hindes R; Iloeje U; Beebe S; Kreter B
    Hepatology; 2010 Sep; 52(3):886-93. PubMed ID: 20683932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver disease-significant improvement with lamivudine.
    Leung N
    J Med Virol; 2000 Jul; 61(3):380-5. PubMed ID: 10861650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
    Tassopoulos NC; Volpes R; Pastore G; Heathcote J; Buti M; Goldin RD; Hawley S; Barber J; Condreay L; Gray DF
    Hepatology; 1999 Mar; 29(3):889-96. PubMed ID: 10051494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study.
    Serfaty L; Thabut D; Zoulim F; Andreani T; Chazouillères O; Carbonell N; Loria A; Poupon R
    Hepatology; 2001 Sep; 34(3):573-7. PubMed ID: 11526544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.